

CURRENT APPROVED PROTOCOLS
SEPTEMBER 2009

*****HIGHLIGHTED STUDIES IN GRAY ARE PENDING (SEE RESEARCH NURSE REGARDING STATUS OF STUDY)*****

BRAIN STUDIES:

RTOG 0825 NEWLY DX. GLIOBLASTOMA- CONCURRENT C/RT & ADJ. TEMODAR+/- BEV **1**

BREAST STUDIES

NEO-ADJUVANT:

C40601 NEOADJ. HER2+ -PACLITAXEL w/TRASTUZUMAB, LAPATINIB OR BOTH **3**

***ADJUVANT:**

C40101 NODE (0-3) +/- HIGH RISK NODE – BC: AC (4 CYCLES) VS PACLITAXEL (4 CYCLES) **5**

E5103 NODE + & HIGH RISK NODE – BC: AC+ T W/ BEVACIZUMAB/PLACEBO **7**

IBCSG 24-02 ADJ. PREMENOPAUSAL ER+ BC: OFS/ER+ AND/OR PR +/- CHEMOTHERAPY **9**

IBCSG 25-02 ADJ. PREMENOPAUSAL ER+ AND/OR PR +/- CHEMO (SOFT) **11**

TAILORx ADJ. BC ER AND/OR PR +, HER2 -, NODE – RISK ASSESMENT **13**

S0221 ADJ. NODE + HIGH RISK NODE – BC: AC/T Q 2 WKS VS WEEKLY **15**

NSABP B-39 STAGE 0, I OR II BC: WBI VS PBI **17**

3144A2-3004-WW ADJ. HER2+ NERATINIB/PLACEBO AFTER TRASTUZUMAB **19**

***ADVANCED/MET:**

C40503 ENDOTHERAPY W/ BEV/PLACEBO HORMONE + ADV. BC **21**

E1105 1ST LINE HER2/NEU+ MET BC: CHEMO + TRASTUZUMAB +/- BEV **23**

G.I. STUDIES

E4203 PREVIOUSLY UNTREATED MET CR: (TS EXP) (IROX + AVASTIN VS FOLFOX/AVASTIN) **25**

E5202 STAGE II COLON (MOLECULAR MARKERS: LOW RISK-OB, HIGH RISK- FOLFOX +/- AVASTIN) **27**

S0518 ADV POOR PROGNOSIS CARCINOID: OCTREOTIDE + INTERFERON VS OCTREOTIDE + BEV **29**

GI 0815 UNRESECTABLE PANCREATIC (ERLOTINIB + SORAFINIB) **31**

RTOG 0436 ESOPHAGEAL- RT/ERBITUX/TAXOL/CISP. VS. RT/TAXOL/CISP. **33**

HEAD & NECK STUDIES

E1305 CHEMOTHERAPY W/WO BEVACIZUMAB IN RECURRENT/MET HN PTS. **35**

HN 0585 REGISTRY STUDY FOR PTS. WITH TX OTHER THAN SURGERY **37**

LEUKEMIA STUDIES

C10501 UNTREATED ASYMPTOMATIC B-CELL CLL (RISK, ASSESS + TX) **39**

LUNG STUDIES

C30607 ADV III B/IV NSCLC/ SUNITINIB AS MAINTANCE AFTER CHEMO **41**

E1505 (STAGE IB ≥ 4CM – IIIA) NSCLC: ADJ. CHEMO +/- BEVACIZUMAB **43**

THO 0632 EXT STAGE SCLC: CARBOPLATIN +ABRAXANE ON 2 DIFFERENT SCHEDULES **45**

MARVEL ADVANCED (NSCLC) RANDOMIZED TO PEMETREXED VS. ERLOTINIB **47**

THO 0746 STAGE III NSCLC: ABRAXANE/CARBOPLATIN + RADIATION THERAPY (PHASE I) **49**

MELANOMA STUDY

S0438 MET MELANOMA SORAFENIB W/ TEMSIROLIMUS OR TIPIFARNIB **51**

MYELOMA STUDY

S0777 UNTREATED MULT MYELOMA – REVLIMID + LOW DOSE DEX VS. VELCADE + LOW DOSE DEX **53**

*****RESEARCH NUMBERS*** :**

MARY GOODNER RN: RESEARCH COORDINATOR: OFFICE: 778-3048 FAX: 778-5131 CELL: 802-9968

MELISSA SINDLER RN: RESEARCH NURSE: OFFICE: 778-3107 MAIN FAX: 778-5131 CELL: 802-8265

SARAH BARRETT, RHIT: RESEARCH ASSISTANT: OFFICE: 778-7847 FAX: 778-6056

******VANDERBILT CANCER INFORMATION PROGRAM**

TELEPHONE: 1-800-811-8480 FAX: 615-936-5794

ECOG

TELEPHONE: 617-632-3610 FAX: 617-632-2990*****

ECOG PERFORMANCE STATUS CRITERIA	KARNOFSKY GRADE	SCALE
0 NORMAL ACTIVITY, FULLY ACTIVE, ABLE TO CARRY ON ALL PRE-DISEASE PERFORMANCE WITHOUT RESTRICTION		(90-100)
1 SYMPTOMS, BUT AMBULATORY, RESTRICTED IN PHYSICALLY STRENUOUS ACTIVITY BUT AMBULATORY AND ABLE TO CARRY OUT WORK OF A LIGHT OR SEDENTARY NATURE (EX: LIGHT HOUSEWORK)		(70-80)
2 IN BED < 50% OF THE TIME, AMBULATORY AND CAPABLE OF ALL SELF-CARE, BUT UNABLE TO CARRY OUT ANY WORK ACTIVITIES UP AND ABOUT MORE THAN 50% OF WAKING HOURS		(50-60)
3 IN BED > 50% OF THE TIME, CAPABLE OF ONLY LIMITED SELF-CARE, CONFINED TO BED OR CHAIR MORE THAN 50% OF TIME		(30-40)
4 100 % BEDRIDDED, COMPLETELY DISABLED, CANNOT CARRY OUT ANY SELF-CARE, TOTALLY CONFINED TO BED OR CHAIR		(10-20)
5 DEAD		(0)